Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Pure autonomic failure may serve as a prodromal manifestation of Parkinson disease, Lewy body dementia, and multiple system atrophy.
The alternative text for this image may have been generated using AI. Using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt2), we inferred the functional ...
MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Multiple system atrophy (MSA) is a neurodegenerative disease characterized by cerebellar ataxia, parkinsonism, and autonomic dysfunction 1. Patients with MSA experience rapid disease progression, ...
Aussie biotech Alterity Therapeutics Ltd. released interim data of an open-label phase II trial for lead candidate ATH-434 for treating multiple system atrophy that showed 43% of participants improved ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results